Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis

Background: Infliximab (IFX) is a potent therapeutic agent used for the treatment of conventional refractory ulcerative colitis (UC). However, the high non-response rate of IFX brings difficulties to clinical applications. In the context of proteomics research, our study of differentially expressed...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lu, Pu, Dan, Wang, Dandan, Zhang, Muhan, Zhou, Chuan, Zhang, Zhe, Feng, Baisui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234463/
https://www.ncbi.nlm.nih.gov/pubmed/35770079
http://dx.doi.org/10.3389/fphar.2022.905133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234463/
https://www.ncbi.nlm.nih.gov/pubmed/35770079
http://dx.doi.org/10.3389/fphar.2022.905133

Ejemplares similares